Archived Content


Day 1  |  Day 2 |  Download Agenda 

Allosteric modulation has taken off recently in applications to the drug discovery arena, especially where G Protein-Coupled Receptors (GPCRs) are involved. Not only can allosteric modulators be developed as drugs to selectively activate specific functions of a GPCR or other target and thereby reduce the risk of side-effects, but allosteric modulators can also be used as tools in drug discovery to decipher the signaling complexities of a GPCR. At Cambridge Healthtech Institute’s inaugural day and a half meeting devoted to Allosteric Modulators, hear case studies about the discovery and optimization of allosteric modulators for GPCRs and a few non-GPCR targets as well.

THURSDAY, NOVEMBER 3

 

Identifying Allosteric Modulators:
Theory and Screening Approaches

1:30 pm Chairperson’s Remarks

Andrew Alt, Ph.D., Senior Research Investigator, Lead Discovery, Bristol Myers Squibb

1:40 KEYNOTE PRESENTATION:

7TM Receptor Drug Discovery: An Allosteric View of Shapeshifting Proteins

Terrence KenakinTerry P. Kenakin, Ph.D., Professor, Department of Pharmacology, University of North Carolina School of Medicine

As new drug screening increasingly uses functional rather than traditional binding assays, allosteric ligands often enter the drug discovery process through happenstance. However the need for specifically designed allosteric screens is growing. The therapeutic potential of allosteric molecules due to their unique properties of permissive, saturable and probe dependent activity is becoming well recognized.This talk discusses properties of allosteric ligands, how they can be detected and procedures for quantifying their activity for lead optimization.

2:40 A Case Study: Evaluating Allosteric Modulators of CCR1 for Multiple Myeloma

Annette Gilchrist, Ph.D., Assistant Professor, Pharmaceutical Sciences, Midwestern University

Osteolytic bone destruction is one of the most frequent complications of multiple myeloma (MM), a clonal B-cell disorder characterized by the accumulation of malignant plasma cells in the bone marrow. Studies have recently emerged that suggest a role for the chemokine receptor CCR1 in multiple myeloma progression. To evaluate the role of CCR1 in MM we used several previously described allosteric small molecule inhibitors. Results from radioactive binding assays, and beta-arrestin translocation assays will be presented.

3:10 Networking Refreshment Break in the Exhibit Hall with Poster Viewing

3:45 Opportunities and Challenges in Developing High-Throughput Screens for Allosteric Modulators of G Protein-Coupled Receptors

Andrew Alt, Ph.D., Senior Research Investigator, Lead Discovery, Bristol Myers Squibb

Allosteric modulation of G protein-coupled receptors is an emerging therapeutic strategy that can potentially provide improved selectivity and safety, along with maintenance of spatial and temporal regulation associated with native receptor signaling. Accordingly, drug discovery efforts at GPCR targets have increasingly focused on the identification of allosteric modulators. This presentation will focus on the special challenges, opportunities and current strategies for high-throughput screening for allosteric GPCR modulators, with particular focus on the identification of positive allosteric modulators.

4:15 Sponsored Presentations (Opportunities Available)

4:45 Positive Allosteric Modulation of Metabotropic Glutamate Receptors in Neurotransmission: Specific Activity-Dependent Regulation of Defined Synaptic Circuits in vivo

Thomas Salt, Ph.D., Professor, Visual Neuroscience, University College London Institute of Ophthalmology

This talk will review use of Positive Allosteric Modulators (PAMs) to enhance mGlu synaptic and extra-synaptic function. I will show how PAMs can affect synaptic function under different physiological and pathological conditions in the whole organism based on recent experimental data on PAM action in thalamic circuitry from various groups (including the presenter’s). This will be placed in the context of how PAMs can affect sensory/pain processes, cognitive processes, schizophrenia, and epileptic mechanisms in vivo.

5:15 Panel Discussion: Screening for Allosteric Modulators

Andrew AltModerator: Andrew Alt, Ph.D., Senior Research Investigator, Lead Discovery, Bristol Myers Squibb




 

Panelists: Terry P. Kenakin, Ph.D., Professor, Department of Pharmacology, University of North Carolina School of Medicine; Scott Kuduk, Ph.D., Senior Research Fellow, Medicinal Chemistry, Merck & Co.; Craig Lindsley, Ph.D., Professor of Pharmacology and Chemistry; Director, Medicinal Chemistry, Vanderbilt Program in Drug Discovery, Vanderbilt University Medical Center

  • What are the potential therapeutic advantages of PAMs (besides receptor subtype selectivity) and how can we exploit these?
  • What is the meaning and relevance of the agonist activity that many PAMs exhibit in addition to their PAM activity in vitro? Is this an artifact of recombinant expression systems? Do mixed ago/PAMs have potential therapeutic advantages?
  • Can allosteric modulators be used to modulate signaling bias? Can a PAM approach be used to avoid receptor desensitization?
  • Are dynamic assays (specifically cAMP assays) different/better than accumulation assays for detecting allosteric modulators?
  • Can expect to discover a large number of native allosteric modulators in the coming years?

5:45 End of Day

 

Day 1  |  Day 2 |  Download Agenda

DOT Hub Icon 

 Short Courses


2015 Discovery on Target Brochure  

2015 BROCHURE


 PREMIER SPONSORS

Cellecta 

Domainex

Molecular Sensing

Rosa Drug Development Advisors

Sigma_NEW

VIEW ALL SPONSORS

VIEW MEDIA PARTNERS


IPR_Micrombiome


SPONSORSHIPS & EXHIBITS

The exhibit hall was sold out in 2014, so please contact us early to reserve your place. To customize your sponsorship or exhibit package for 2015, contact:

Jon Stroup
Sr. Business Development Manager
781-972-5483
jstroup@healthtech.com


 
 

September 21 

Next-Generation Histone Deacetylase Inhibitors Symposia 

Strategies for Rare Diseases Symposia 

September 22 

Developing CRISPR-Based Therapies Symposia 

September 22 - 23 

Targeting Epigenetic Readers and Chromatin Remodelers 

Targeting the Ubiquitin Proteasome System 

Targeting the Microbiome 

GPCR - Based Drug Discovery - Part 1 

Antibodies Against Membrane Protein Targets - Part 1 

RNAi for Functional Genomics Screening 

Gene Therapy Breakthroughs 

Targeting Ocular Disorders 

September 23 - 24 

Targeting Histone Methyltransferases and Demethylases 

Targeting the Unfolded Protein Response 

Kinase Inhibitor Discovery 

GPCR-Based Drug Discovery - Part 2 

Antibodies Against Membrane Protein Targets - Part 2 

New Frontiers in Gene Editing 

Quantitative Systems Pharmacology 

Short Courses 

SC1: Cancer Metabolism: Pathways, Targets and Clinical Updates 

SC2: Leveraging Data and Analytics for Drug DiSCovery 

SC3: Setting Up Effective Rnai SCreens: From Design to Data to Validation 

SC4: Phenotypic SCreening and Chemical Probe Development 

SC5: GPCR Structure-based Drug Discovery 

SC6: Targeting of GPCRs with Monoclonal Antibodies 

SC7: Setting Up Effective Functional SCreens Using 3D Cell Cultures 

SC8: Targeting Protein-protein Interactions: Biophysical Approaches 

SC9: Preclinical Animal Models for Ocular Indications 

SC10: Introduction to Allosteric Modulators and Biased Ligands of GPCRs 

SC11: Introduction to Targeted Covalent Inhibitors 

SC12: Assays and High-throughput SCreening for Novel Epigenetic Inhibitors 

SC13: Gamification and Drug Target Challenges 

SC14: A Primer to Gene Editing: Tools and Applications 

SC15: Using Mechanistic Physiological Models In Drug Development